Resmed Inc DRC (RMD)

Currency in AUD
28.630
-0.100(-0.35%)
Delayed Data·
RMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.50028.930
52 wk Range
28.40045.250
Key Statistics
Bid/Ask
28.63 / 28.65
Prev. Close
28.73
Open
28.79
Day's Range
28.5-28.93
52 wk Range
28.4-45.25
Volume
845.95K
Average Volume (3m)
1.32M
1-Year Change
-23.1347%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.550
Upside
+52.11%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years

Resmed Inc DRC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 43.550
(+52.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
CLSA
Buy38.50+34.43%42.25MaintainApr 28, 2026
JPMorgan
Buy---New CoverageApr 15, 2026
CLSA
Buy45.25+58.00%47.25MaintainJan 26, 2026
Citi
Buy51.00+78.07%49.00MaintainSep 18, 2025
CLSA
Buy47.25+64.98%46.00UpgradeSep 02, 2025

Earnings

Latest Release
Jan 30, 2026
EPS / Forecast
2.68 / --
Revenue / Forecast
1.42B / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.11%
Dividend Yield
1.18%
Industry Median 1.04%
Annualized payout
0.35
Paid unevenly
5-Years Growth
+7.70%
Growth Streak

RMD Income Statement

Compare RMD to Peers and Sector

Metrics to compare
RMD
Peers
Sector
Relationship
P/E Ratio
20.0x16.7x−0.5x
PEG Ratio
-0.360.00
Price/Book
4.7x1.8x2.6x
Price / LTM Sales
5.5x1.6x3.3x
Upside (Analyst Target)
56.2%27.4%47.7%
Fair Value Upside
Unlock29.6%6.6%Unlock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Employees
10600
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
62.96M43.41%1.81B
Other Institutional Investors
48.35M33.33%1.39B
Public Companies & Retail Investors
33.74M23.26%969.46M
Total
145.06M100.00%4.17B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.13.71%19,881,790571,204
BlackRock, Inc.8.64%12,529,652359,977

People Also Watch

137.11
PME
+0.70%
28.22
TNE
+0.97%
2.675
MTS
-0.93%
42.71
SOL
+0.40%
101.46
COH
+2.72%

FAQ

What Is the Resmed DRC (RMD) Stock Price Today?

The Resmed DRC stock price today is 28.630 AUD.

What Stock Exchange Does Resmed DRC Trade On?

Resmed DRC is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Resmed DRC?

The stock symbol for Resmed DRC is "RMD."

Does Resmed DRC Pay Dividends? What’s The Current Dividend Yield?

The Resmed DRC dividend yield is 1.18%.

What Is the Resmed DRC Market Cap?

As of today, Resmed DRC market cap is 41.270B AUD.

What Is Resmed DRC's Earnings Per Share (TTM)?

The Resmed DRC EPS (TTM) is 10.111.

From a Technical Analysis Perspective, Is RMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Resmed DRC Stock Split?

Resmed DRC has split 3 times.

How Many Employees Does Resmed DRC Have?

Resmed DRC has 10600 employees.

What is the current trading status of Resmed DRC (RMD)?

As of May 04, 2026, Resmed DRC (RMD) is trading at a price of 28.630 AUD, with a previous close of 28.730 AUD. The stock has fluctuated within a day range of 28.500 AUD to 28.930 AUD, while its 52-week range spans from 28.400 AUD to 45.250 AUD.

What Is Resmed DRC (RMD) Price Target According to Analysts?

The average 12-month price target for Resmed DRC is 43.550 AUD, with a high estimate of 48.97307799 AUD and a low estimate of 36.89703025 AUD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +52.11% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.